Johnson & Johnson JNJ

Pharmaceuticals & medical devices. Johnson & Johnson, listed on NYSE.

Based on the FY2025 annual report (Dec 2024 – Dec 2025)

Johnson & Johnson's market cap is
about $666.8 billion.

#15 by market cap among 289 companies, based on the Nov 5, 2026 close. FY2025 revenue was $94.193B.

Share price (close): $272.32; Close on Nov 5, 2026 · per share
P/E ratio: 24.7x; Closing price ÷ latest annual EPS
Market cap: $666.8B; #15 of 289
Revenue: $94.193B; #38 of 299 · +6.0% YoY
Operating income: —; Not reported
Net income: $26.804B; #12 of 298 · +90.6% YoY
Free cash flow: $19.698B; #14 of 261 · −0.7% YoY
Total assets: $199.21B; #42 of 299 · +10.6% YoY
Dividends paid: —; Not reported
Dividend per share: $5.14; #44 of 205 · +4.7% YoY
Dividend yield: 1.9%; #88 of 203
Shares outstanding: 2,429,400,000 shares; As of Dec 28, 2025

Size, put in perspective

Revenue every second$2,990$258M a day

Net income every second$850$73.4M a day

Buying AbbVie with a year's profit5.2% of itBased on AbbVie's market cap of about $510.8 billion

Market cap vs AbbVie1.3×Johnson & Johnson ÷ AbbVie

Calculated from the FY2025 annual report, spread evenly over 365 days.

Where the revenue went

Revenue is set at 100% and split into what went to costs, R&D, operating expenses and taxes, and what was left as profit.

Cost of revenue32.1%
R&D0.1%
Other expenses33.2%
Income taxes & other6.1%
Net income28.5%

Profitability and stability

Each figure comes with its rank among 300 companies. The further right the dot, the higher the rank.

Revenue growthHow much revenue grew from the previous fiscal year: +6.0%; #183 of 299; Revenue is growing steadily. The median across 299 companies is +7.9%.
Operating marginShare of revenue kept as profit from the core business: —; Not ranked; The filing doesn't include the items needed to calculate this.
Net marginShare of revenue left as profit after interest and taxes: 28.5%; #44 of 298; After taxes, 28.5% of revenue was left as net income. The median across 298 companies is 14.0%.
FCF marginShare of revenue left as cash after capital spending: 20.9%; #83 of 261; Plenty of cash is left after capital spending. The median across 261 companies is 15.8%.
ROEHow much profit the company earned on shareholders' equity in a year: 35.0%; #69 of 276; Earns a lot relative to its equity. The median across 276 companies is 16.8%.
Debt-to-equityLiabilities relative to equity. Lower means less debt: 144.3%; #107 of 244; Liabilities exceed equity. The median across 244 companies is 159.6%.

Revenue and profit over time

Gray bars show revenue and the green part inside shows net income. The number above each bar is revenue (abbreviated) and the number below is net margin. Hover over a bar to see the exact amounts.

Currency: US dollars. Years are the years in which each fiscal year ended.

Where the cash went

Unlike profit, cash flow is money that actually came in and went out.

Cash from operations$24.53B
Capital spending−$4.832B
Free cash flow (FCF)$19.698B

Whose money funds the assets

The company's assets, split into borrowed money (liabilities) and shareholders' money (equity).

Liabilities 59%Equity 41%

Total assets$199.21B
Total liabilities$117.666B
Total equity$81.544B
Cash and equivalents$19.709B

Compared with similar companies

Based on each company's latest annual report, so fiscal year ends may differ.

Compare in detail

Company	Annual revenue	Net income	Revenue growth	Operating margin	Net margin
Johnson & JohnsonJNJ	$94.193B	$26.804B	+6.0%	—	28.5%
AbbVieABBV	$61.16B	$4.226B	+8.6%	24.6%	6.9%
Eli LillyLLY	$65.179B	$20.64B	+44.7%	—	31.7%
MerckMRK	$65.011B	$18.254B	+1.3%	—	28.1%
PfizerPFE	$62.579B	$7.771B	−1.6%	—	12.4%

Head-to-head comparisons

What the company does

Johnson & Johnson makes prescription drugs, such as cancer and immunology treatments, and surgical and cardiovascular medical devices. It spun off its consumer health business as Kenvue in 2023.

The fiscal year ends around December each year.

Related companies: AbbVie, Eli Lilly, Merck, Pfizer

Financial statements

Last 5 fiscal years. Currency: US dollars.

Show the table

Item	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	78.74B	79.99B	85.159B	88.821B	94.193B
Cost of revenue	23.402B	24.596B	26.553B	27.471B	30.256B
Gross profit	55.338B	55.394B	58.606B	61.35B	63.937B
R&D expense	0	0	483M	1.841B	109M
Pretax income	19.178B	19.359B	15.062B	16.687B	32.581B
Net income	20.878B	17.941B	35.153B	14.066B	26.804B
EPS (diluted)	$7.81	$6.73	$13.72	$5.79	$11.03
Operating cash flow	23.41B	21.194B	22.791B	24.266B	24.53B
Capital expenditures	3.652B	4.009B	4.543B	4.424B	4.832B
Free cash flow (FCF)	19.758B	17.185B	18.248B	19.842B	19.698B
Total assets	182.018B	187.378B	167.558B	180.104B	199.21B
Total liabilities	107.995B	110.574B	98.784B	108.614B	117.666B
Total equity	74.023B	76.804B	68.774B	71.49B	81.544B
Cash and equivalents	14.487B	14.127B	21.859B	24.105B	19.709B
Original filing	10-K	10-K	10-K	10-K	10-K

Source: SEC EDGAR filings for Johnson & Johnson · CIK 0000200406 · US-GAAP